{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:40Z","timestamp":1790769340932,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":17,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_15","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:30Z","timestamp":1790764470000},"page":"227-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening and Evaluation Scheme for the Identification of Antisense Oligonucleotides with Antiviral Activity Against SARS-CoV-2"],"prefix":"10.1007","author":[{"given":"Masako","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"6","key":"15_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Baker BF, Crooke RM, Liang XH (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20(6):427\u2013453. https:\/\/doi.org\/10.1038\/s41573-021-00162-z","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"15_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim D et al (2020) The architecture of SARS-CoV-2 transcriptome. Cell 181(4):914\u2013921.e910. https:\/\/doi.org\/10.1016\/j.cell.2020.04.011","journal-title":"Cell"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","volume":"59","author":"S Dro\u017cd\u017cal","year":"2021","unstructured":"Dro\u017cd\u017cal S et al (2021) An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat 59:100794. https:\/\/doi.org\/10.1016\/j.drup.2021.100794","journal-title":"Drug Resist Updat"},{"key":"15_CR4","doi-asserted-by":"publisher","first-page":"105372","DOI":"10.1016\/j.antiviral.2022.105372","volume":"205","author":"H Ohashi","year":"2022","unstructured":"Ohashi H et al (2022) Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 omicron subvariants, BA.1 and BA.2. Antiviral Res 205:105372. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105372","journal-title":"Antiviral Res"},{"issue":"7","key":"15_CR5","doi-asserted-by":"publisher","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","volume":"73","author":"M Martinot","year":"2021","unstructured":"Martinot M et al (2021) Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019. Clin Infect Dis 73(7):e1762\u2013e1765. https:\/\/doi.org\/10.1093\/cid\/ciaa1474","journal-title":"Clin Infect Dis"},{"issue":"656","key":"15_CR6","doi-asserted-by":"publisher","first-page":"eabo0718","DOI":"10.1126\/scitranslmed.abo0718","volume":"14","author":"LJ Stevens","year":"2022","unstructured":"Stevens LJ et al (2022) Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med 14(656):eabo0718. https:\/\/doi.org\/10.1126\/scitranslmed.abo0718","journal-title":"Sci Transl Med"},{"key":"15_CR7","doi-asserted-by":"publisher","unstructured":"Jochmans D et al (2023) The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. mBio 14(1):e0281522. https:\/\/doi.org\/10.1128\/mbio.02815-22","DOI":"10.1128\/mbio.02815-22"},{"issue":"12","key":"15_CR8","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/17460441.2022.2153828","volume":"17","author":"P Pagliano","year":"2022","unstructured":"Pagliano P et al (2022) The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19. Expert Opin Drug Discov 17(12):1299\u20131311. https:\/\/doi.org\/10.1080\/17460441.2022.2153828","journal-title":"Expert Opin Drug Discov"},{"issue":"13","key":"15_CR9","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama S et al (2020) Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 117(13):7001\u20137003. https:\/\/doi.org\/10.1073\/pnas.2002589117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"105992","DOI":"10.1016\/j.antiviral.2024.105992","volume":"230","author":"M Yamasaki","year":"2024","unstructured":"Yamasaki M et al (2024) Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA. Antiviral Res 230:105992. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105992","journal-title":"Antiviral Res"},{"issue":"1","key":"15_CR11","doi-asserted-by":"publisher","first-page":"eabh3827","DOI":"10.1126\/sciadv.abh3827","volume":"8","author":"N Iwata-Yoshikawa","year":"2022","unstructured":"Iwata-Yoshikawa N et al (2022) A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. Sci Adv 8(1):eabh3827. https:\/\/doi.org\/10.1126\/sciadv.abh3827","journal-title":"Sci Adv"},{"issue":"6","key":"15_CR12","doi-asserted-by":"publisher","first-page":"e1010590","DOI":"10.1371\/journal.ppat.1010590","volume":"18","author":"W Saso","year":"2022","unstructured":"Saso W et al (2022) Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2. PLoS Pathog 18(6):e1010590. https:\/\/doi.org\/10.1371\/journal.ppat.1010590","journal-title":"PLoS Pathog"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"802766","DOI":"10.3389\/fchem.2021.802766","volume":"9","author":"S Hegde","year":"2021","unstructured":"Hegde S, Tang Z, Zhao J, Wang J (2021) Inhibition of SARS-CoV-2 by targeting conserved viral RNA structures and sequences. Front Chem 9:802766. https:\/\/doi.org\/10.3389\/fchem.2021.802766","journal-title":"Front Chem"},{"key":"15_CR14","doi-asserted-by":"publisher","unstructured":"Chang CW et al (2022) A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. Viruses 14(7). https:\/\/doi.org\/10.3390\/v14071369","DOI":"10.3390\/v14071369"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coviro.2021.03.009","volume":"48","author":"CY Lee","year":"2021","unstructured":"Lee CY, Lowen AC (2021) Animal models for SARS-CoV-2. Curr Opin Virol 48:73\u201381. https:\/\/doi.org\/10.1016\/j.coviro.2021.03.009","journal-title":"Curr Opin Virol"},{"key":"15_CR16","doi-asserted-by":"publisher","unstructured":"Tamil Selvan M et al (2022) SARS CoV-2 (delta variant) infection kinetics and immunopathogenesis in domestic cats. Viruses 14(6):1207. https:\/\/doi.org\/10.3390\/v14061207","DOI":"10.3390\/v14061207"},{"issue":"1","key":"15_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun SH et al (2020) A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28(1):124\u2013133.e124. https:\/\/doi.org\/10.1016\/j.chom.2020.05.020","journal-title":"Cell Host Microbe"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:03:05Z","timestamp":1790766185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":17,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_15","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}